Copper-adenine complex, a compound, with multi-biochemical targets and potential anti-cancer effect

Hassan H. Hammud; Georges Nemer; Walid Sawma; Jhonny Touma; Pascale Barnabe; Yolla Bou-Mouglabey; Amer Ghannoum; Jida El-Hajjar; Julnar Usta

doi:10.1016/j.cbi.2008.03.005

Copper-adenine complex, a compound, with multi-biochemical targets and potential anti-cancer effect

Hassan H. Hammud, Georges Nemer, Walid Sawma, Jhonny Touma, Pascale Barnabe, Yolla Bou-Mouglabey, Amer Ghannoum, Jida El-Hajjar, Julnar Usta^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

45 Citations (Scopus)

Abstract

A series of adenine-copper complexes (1-6) with various ligands (Cl^-, SCN^-, BF₄^- and acac [acetylacetonate ion]) have been synthesized and characterized by elemental analysis, infrared spectroscopy and thermal analysis. Among the six complexes only complex (1), Cu₂(adenine)₄Cl₄·2EtOH (abbreviated as Cu-Ad), demonstrated some toxic effect on different cell lines. In vitro investigations of the biological effect of Cu-Ad complex have shown that it: (1) binds genomic DNA; (2) decreases significantly, the viability of cells in culture in a concentration (15-125 μM)-dependant manner; an estimated IC₅₀ of: 45 μM with HepG2; 73 μM with C2C12; 103 μM with NIH3T3; and 108 μM with MCF7. Cu-Ad had no effect on A549 cells; (3) inhibits Taq polymerase-catalyzed reaction; (4) inhibits the binding of the transcription factor GATA-5 to labeled DNA probes; (5) inhibits mitochondrial NADH-UQ-reductase with an estimated IC₅₀ of 2.8 nmol, but had no effect on succinate dehydrogenase activity; (6) increases reactive oxygen species (60%) at 45 μM Cu-Ad; and (7) decreases ATP (80%) at 50 μM Cu-Ad. The new compound Cu₂(adenine)₄Cl₄·2EtOH (Cu-Ad), belongs to a class of copper-adenylate complexes that target many biochemical sites and with potential anti-cancer activity.

Original language	English
Pages (from-to)	84-96
Number of pages	13
Journal	Chemico-Biological Interactions
Volume	173
Issue number	2
DOIs	https://doi.org/10.1016/j.cbi.2008.03.005
Publication status	Published - 28 May 2008
Externally published	Yes

Keywords

Copper-adenine
GATA-5
HepG2
PCR
TbX20
WND

Access to Document

10.1016/j.cbi.2008.03.005

Cite this

@article{a4ca96c322dd4a929e05b3ac27f00b80,

title = "Copper-adenine complex, a compound, with multi-biochemical targets and potential anti-cancer effect",

abstract = "A series of adenine-copper complexes (1-6) with various ligands (Cl-, SCN-, BF4- and acac [acetylacetonate ion]) have been synthesized and characterized by elemental analysis, infrared spectroscopy and thermal analysis. Among the six complexes only complex (1), Cu2(adenine)4Cl4·2EtOH (abbreviated as Cu-Ad), demonstrated some toxic effect on different cell lines. In vitro investigations of the biological effect of Cu-Ad complex have shown that it: (1) binds genomic DNA; (2) decreases significantly, the viability of cells in culture in a concentration (15-125 μM)-dependant manner; an estimated IC50 of: 45 μM with HepG2; 73 μM with C2C12; 103 μM with NIH3T3; and 108 μM with MCF7. Cu-Ad had no effect on A549 cells; (3) inhibits Taq polymerase-catalyzed reaction; (4) inhibits the binding of the transcription factor GATA-5 to labeled DNA probes; (5) inhibits mitochondrial NADH-UQ-reductase with an estimated IC50 of 2.8 nmol, but had no effect on succinate dehydrogenase activity; (6) increases reactive oxygen species (60%) at 45 μM Cu-Ad; and (7) decreases ATP (80%) at 50 μM Cu-Ad. The new compound Cu2(adenine)4Cl4·2EtOH (Cu-Ad), belongs to a class of copper-adenylate complexes that target many biochemical sites and with potential anti-cancer activity.",

keywords = "Copper-adenine, GATA-5, HepG2, PCR, TbX20, WND",

author = "Hammud, {Hassan H.} and Georges Nemer and Walid Sawma and Jhonny Touma and Pascale Barnabe and Yolla Bou-Mouglabey and Amer Ghannoum and Jida El-Hajjar and Julnar Usta",

year = "2008",

month = may,

day = "28",

doi = "10.1016/j.cbi.2008.03.005",

language = "English",

volume = "173",

pages = "84--96",

journal = "Chemico-Biological Interactions",

issn = "0009-2797",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Copper-adenine complex, a compound, with multi-biochemical targets and potential anti-cancer effect

AU - Hammud, Hassan H.

AU - Nemer, Georges

AU - Sawma, Walid

AU - Touma, Jhonny

AU - Barnabe, Pascale

AU - Bou-Mouglabey, Yolla

AU - Ghannoum, Amer

AU - El-Hajjar, Jida

AU - Usta, Julnar

PY - 2008/5/28

Y1 - 2008/5/28

N2 - A series of adenine-copper complexes (1-6) with various ligands (Cl-, SCN-, BF4- and acac [acetylacetonate ion]) have been synthesized and characterized by elemental analysis, infrared spectroscopy and thermal analysis. Among the six complexes only complex (1), Cu2(adenine)4Cl4·2EtOH (abbreviated as Cu-Ad), demonstrated some toxic effect on different cell lines. In vitro investigations of the biological effect of Cu-Ad complex have shown that it: (1) binds genomic DNA; (2) decreases significantly, the viability of cells in culture in a concentration (15-125 μM)-dependant manner; an estimated IC50 of: 45 μM with HepG2; 73 μM with C2C12; 103 μM with NIH3T3; and 108 μM with MCF7. Cu-Ad had no effect on A549 cells; (3) inhibits Taq polymerase-catalyzed reaction; (4) inhibits the binding of the transcription factor GATA-5 to labeled DNA probes; (5) inhibits mitochondrial NADH-UQ-reductase with an estimated IC50 of 2.8 nmol, but had no effect on succinate dehydrogenase activity; (6) increases reactive oxygen species (60%) at 45 μM Cu-Ad; and (7) decreases ATP (80%) at 50 μM Cu-Ad. The new compound Cu2(adenine)4Cl4·2EtOH (Cu-Ad), belongs to a class of copper-adenylate complexes that target many biochemical sites and with potential anti-cancer activity.

AB - A series of adenine-copper complexes (1-6) with various ligands (Cl-, SCN-, BF4- and acac [acetylacetonate ion]) have been synthesized and characterized by elemental analysis, infrared spectroscopy and thermal analysis. Among the six complexes only complex (1), Cu2(adenine)4Cl4·2EtOH (abbreviated as Cu-Ad), demonstrated some toxic effect on different cell lines. In vitro investigations of the biological effect of Cu-Ad complex have shown that it: (1) binds genomic DNA; (2) decreases significantly, the viability of cells in culture in a concentration (15-125 μM)-dependant manner; an estimated IC50 of: 45 μM with HepG2; 73 μM with C2C12; 103 μM with NIH3T3; and 108 μM with MCF7. Cu-Ad had no effect on A549 cells; (3) inhibits Taq polymerase-catalyzed reaction; (4) inhibits the binding of the transcription factor GATA-5 to labeled DNA probes; (5) inhibits mitochondrial NADH-UQ-reductase with an estimated IC50 of 2.8 nmol, but had no effect on succinate dehydrogenase activity; (6) increases reactive oxygen species (60%) at 45 μM Cu-Ad; and (7) decreases ATP (80%) at 50 μM Cu-Ad. The new compound Cu2(adenine)4Cl4·2EtOH (Cu-Ad), belongs to a class of copper-adenylate complexes that target many biochemical sites and with potential anti-cancer activity.

KW - Copper-adenine

KW - GATA-5

KW - HepG2

KW - PCR

KW - TbX20

KW - WND

UR - http://www.scopus.com/inward/record.url?scp=43049183307&partnerID=8YFLogxK

U2 - 10.1016/j.cbi.2008.03.005

DO - 10.1016/j.cbi.2008.03.005

M3 - Article

C2 - 18452907

AN - SCOPUS:43049183307

SN - 0009-2797

VL - 173

SP - 84

EP - 96

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

IS - 2

ER -

Copper-adenine complex, a compound, with multi-biochemical targets and potential anti-cancer effect

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this